Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022
Tranquis Therapeutics presents at the Stifel CNS Days 2022 Tranquis Therapeutics presents at the 2022 Bio CEO & Investor Forum ALS News Today: TQS-168 Found to Reduce Inflammation, Extend Survival in Mice The small molecule myeloid cell modulator TQS 168 normalizes the inflammatory phenotype of immune cells from ALS patients and extends survival in the SOD1*G93A ALS mouse model Fireside Chat with Mike Ward of Decision Resources and CEO Sanjay Kakkar
Press releases
Events & publications
March 29, 2022
February 14-16, 2022
November 12, 2021
November 8, 2021
E. Chavez Juan, D. Ness, B. Ajami, N. Schwartz, J. Hannestad, S. Kakkar and H. Lancero. Presented at Neuroscience, November 8-11, 2021.
November 17, 2020